GlassScriptPhysician profile
Lisa Hertz
NPI 1639237720
$11,195.29
in general payments reported to CMS, 2019-2025
35 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $1,160 · 2021: $1,196 · 2022: $1,916 · 2023: $1,612 · 2024: $1,875 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,948.88 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,556.86 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $822.12 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $710.25 | 2019-2025 | Tremfya, Simponi, Stelara |
| Merck Sharp & Dohme LLC | $588.78 | 2019-2024 | Dificid |
| Pfizer INC. | $569.31 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $515.84 | 2019-2025 | Linzess |
| Qol Medical, LLC | $416.16 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $341.34 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $270.01 | 2020-2023 | |
| Genzyme Corporation | $262.94 | 2023-2025 | |
| Celgene Corporation | $262.10 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $229.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $213.13 | 2023-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $193.29 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $185.93 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $178.08 | 2023-2025 | Voquezna |
| Vivus LLC | $145.39 | 2022-2023 | Qsymia |
| Ferring Pharmaceuticals INC. | $109.79 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $98.06 | 2022-2025 | Dupixent |
| Shire North American Group INC | $82.10 | 2019 | |
| Exact Sciences Corporation | $77.65 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $66.94 | 2024-2025 | Omvoh |
| Allergan, INC. | $57.16 | 2019-2020 | |
| Albireo Pharma, INC. | $46.55 | 2024 | Iqirvo |
| Intra-Sana Laboratories | $36.09 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Fresenius Kabi USA, LLC | $34.49 | 2024 | |
| Xeris Pharmaceuticals, INC. | $34.21 | 2022-2023 | Keveyis |
| Novo Nordisk INC | $26.41 | 2025 | Wegovy |
| Alfasigma USA, INC. | $24.50 | 2020 | |
| Biocon Biologics INC | $21.71 | 2025 | Hulio |
| Braintree Laboratories, INC. | $18.35 | 2025 | Suflave |
| Celltrion USA INC. | $17.43 | 2024 | Vegzelma |
| W. L. Gore & Associates, INC. | $17.18 | 2022 | |
| Redhill Biopharma INC. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.